Form 4: Neurogene Inc. Officer Stuart Cobb Reports Sale of Common Stock
SEC Form 4 Filing
Stuart Cobb, Chief Scientific Officer of Neurogene Inc., reports the sale of 6,797 shares of common stock at a weighted average price of $15.1542, pursuant to a pre-arranged 10b5-1 trading plan.
Summary
- On May 14, 2025, Stuart Cobb, the Chief Scientific Officer of Neurogene Inc., sold 6,797 shares of common stock.
- The sale was executed under a pre-arranged 10b5-1 trading plan adopted on February 6, 2025.
- The shares were sold at a weighted average price of $15.1542, with individual transaction prices ranging from $14.78 to $15.75.
- Following the reported transaction, Cobb beneficially owns 20,794 shares of Neurogene Inc. common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to an executive's stock sale under a pre-arranged plan, indicating a neutral sentiment.
Industry Context
Executive stock sales are a common occurrence and are often related to personal financial planning. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on inside information.
Key Dates
| Date | Description |
|---|---|
| February 6, 2025 | Date of adoption of the 10b5-1 trading plan. |
| May 14, 2025 | Date of the stock sale transaction. |
| May 15, 2025 | Date of the Power of Attorney execution. |
Keywords
Form 4, Neurogene Inc., Stuart Cobb, Stock Sale, 10b5-1 Plan, Officer Transaction, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.